This is the logo of the provider
UEG 2025 4 - 7 October 2025

Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo

Authors :

Mary E. Rinella1; Manal F. Abdelmalek2; Elisabetta Bugianesi3; Laurent Castera4,5; Kristiane A. Engebretsen6; Jacob George7; Wah Kheong Chan8; Niels Krarup6; Michelle T. Long6; Philip N. Newsome9,10; Cláudia P. Oliveira11; Georgios Papatheodoridis12; Ahsan Shoeb6; Salvatore Petta13; Michael Roden14,15,16; Arun J. Sanyal17; Yusuf Yilmaz18; Vlad Ratziu19; on behalf of the ESSENCE study group

Affiliations
View Details Hide Details
Download poster (.pdf)
Keywords
MASH
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)